Spots Global Cancer Trial Database for sapanisertib
Every month we try and update this database with for sapanisertib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors | NCT02197572 | Advanced Solid ... | Sapanisertib | 18 Years - | Calithera Biosciences, Inc | |
| Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer | NCT02417701 | Recurrent Lung ... Stage IV Lung S... | Laboratory Biom... Pharmacological... Sapanisertib | 18 Years - | National Cancer Institute (NCI) | |
| Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer | NCT02049957 | Breast Cancer | Sapanisertib Fulvestrant Exemestane | 18 Years - | Calithera Biosciences, Inc | |
| A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies | NCT02412722 | Non-hematologic... | Sapanisertib Paclitaxel | 18 Years - | Takeda | |
| Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | NCT02159989 | Advanced Malign... Fibrolamellar C... Metastatic Mali... Ovarian Carcino... Pancreatic Neur... Recurrent Malig... Refractory Mali... Unresectable So... | Sapanisertib Ziv-Aflibercept | 18 Years - | National Cancer Institute (NCI) | |
| Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy | NCT02756364 | Breast Neoplasm... | Fulvestrant Sapanisertib | 18 Years - | Calithera Biosciences, Inc | |
| A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies | NCT02412722 | Non-hematologic... | Sapanisertib Paclitaxel | 18 Years - | Takeda | |
| Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia | NCT02484430 | B Acute Lymphob... B Acute Lymphob... B Acute Lymphob... Recurrent Adult... Refractory Adul... T Acute Lymphob... | Laboratory Biom... Pharmacological... Sapanisertib | 18 Years - | National Cancer Institute (NCI) | |
| A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies | NCT02412722 | Non-hematologic... | Sapanisertib Paclitaxel | 18 Years - | Takeda | |
| Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer | NCT02417701 | Recurrent Lung ... Stage IV Lung S... | Laboratory Biom... Pharmacological... Sapanisertib | 18 Years - | National Cancer Institute (NCI) | |
| Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations | NCT03047213 | Locally Advance... Metastatic Tran... Metastatic Urot... Recurrent Bladd... Stage III Bladd... Stage IV Bladde... | Sapanisertib | 18 Years - | National Cancer Institute (NCI) | |
| Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer | NCT04479306 | Recurrent Lung ... Stage IIIB Lung... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Alisertib Osimertinib Sapanisertib | 18 Years - | M.D. Anderson Cancer Center | |
| TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors | NCT02142803 | Adult Glioblast... Endometrial Cle... Endometrial Ser... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Serous ... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Solid Neoplasm Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... | Bevacizumab Laboratory Biom... Pharmacological... Sapanisertib | 18 Years - | National Cancer Institute (NCI) | |
| Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | NCT02159989 | Advanced Malign... Fibrolamellar C... Metastatic Mali... Ovarian Carcino... Pancreatic Neur... Recurrent Malig... Refractory Mali... Unresectable So... | Sapanisertib Ziv-Aflibercept | 18 Years - | National Cancer Institute (NCI) | |
| Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma | NCT02601209 | High Grade Sarc... Metastatic Leio... Metastatic Mali... Metastatic Syno... Metastatic Undi... Metastatic Unre... Myxofibrosarcom... Recurrent Leiom... Recurrent Malig... Recurrent Synov... Recurrent Undif... Stage III Uteri... Stage IIIA Uter... Stage IIIB Uter... Stage IIIC Uter... Stage IV Uterin... Stage IVA Uteri... Stage IVB Uteri... Unresectable Le... | Pazopanib Pazopanib Hydro... Sapanisertib | 18 Years - | National Cancer Institute (NCI) | |
| Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial) | NCT04267913 | Lung Squamous C... Recurrent Lung ... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Dexamethasone Docetaxel Ramucirumab Sapanisertib | - | SWOG Cancer Research Network | |
| TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors | NCT02142803 | Adult Glioblast... Endometrial Cle... Endometrial Ser... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Serous ... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Solid Neoplasm Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... | Bevacizumab Laboratory Biom... Pharmacological... Sapanisertib | 18 Years - | National Cancer Institute (NCI) | |
| Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L) | NCT06385496 | Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult... | Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Sapanisertib | 18 Years - | National Cancer Institute (NCI) | |
| Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M) | NCT06390865 | Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult... | Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Sapanisertib | 18 Years - | National Cancer Institute (NCI) | |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | NCT02465060 | Advanced Lympho... Advanced Malign... Bladder Carcino... Breast Carcinom... Cervical Carcin... Colon Carcinoma Colorectal Carc... Endometrial Car... Esophageal Carc... Gastric Carcino... Glioma Head and Neck C... Hematopoietic a... Kidney Carcinom... Liver Carcinoma Lung Carcinoma Lymphoma Malignant Uteri... Melanoma Multiple Myelom... Ovarian Carcino... Pancreatic Carc... Prostate Carcin... Rectal Carcinom... Recurrent Bladd... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Color... Recurrent Esoph... Recurrent Gastr... Recurrent Gliom... Recurrent Head ... Recurrent Liver... Recurrent Lung ... Recurrent Lymph... Recurrent Malig... Recurrent Melan... Recurrent Multi... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Skin ... Recurrent Thyro... Recurrent Uteri... Refractory Lymp... Refractory Mali... Refractory Mult... Skin Carcinoma Thyroid Gland C... Uterine Corpus ... | Adavosertib Afatinib Afatinib Dimale... Binimetinib Biopsy Biospecimen Col... Capivasertib Computed Tomogr... Copanlisib Copanlisib Hydr... Crizotinib Cytology Specim... Dabrafenib Dabrafenib Mesy... Dasatinib Defactinib Defactinib Hydr... Echocardiograph... Erdafitinib Fexagratinib Ipatasertib Laboratory Biom... Larotrectinib Larotrectinib S... Magnetic Resona... Multigated Acqu... Nivolumab Osimertinib Palbociclib Pertuzumab PI3K-beta Inhib... Radiologic Exam... Radionuclide Im... Relatlimab Sapanisertib Sunitinib Malat... Taselisib Trametinib Trastuzumab Trastuzumab Emt... Ulixertinib Vismodegib | 18 Years - | National Cancer Institute (NCI) | |
| Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study | NCT05022394 | Lung Non-Small ... Recurrent Lung ... Stage I Lung Ca... Stage II Lung C... Stage IIA Lung ... Stage IIB Lung ... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Nivolumab Sapanisertib | 18 Years - | M.D. Anderson Cancer Center | |
| Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer | NCT02503722 | Metastatic Lung... Recurrent Lung ... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... Stage IV Lung N... | Laboratory Biom... Osimertinib Pharmacological... Sapanisertib | 18 Years - | National Cancer Institute (NCI) | |
| Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer | NCT04479306 | Recurrent Lung ... Stage IIIB Lung... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Alisertib Osimertinib Sapanisertib | 18 Years - | M.D. Anderson Cancer Center | |
| Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery | NCT02893930 | Pancreatic Neur... Pancreatic Neur... Refractory Panc... | Sapanisertib | 18 Years - | National Cancer Institute (NCI) | |
| Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer | NCT02417701 | Recurrent Lung ... Stage IV Lung S... | Laboratory Biom... Pharmacological... Sapanisertib | 18 Years - | National Cancer Institute (NCI) | |
| Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial) | NCT04267913 | Lung Squamous C... Recurrent Lung ... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Dexamethasone Docetaxel Ramucirumab Sapanisertib | - | SWOG Cancer Research Network | |
| Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors | NCT03430882 | Recurrent Malig... Refractory Mali... | Carboplatin Paclitaxel Sapanisertib | 18 Years - | M.D. Anderson Cancer Center | |
| Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers | NCT03017833 | Advanced Malign... Metastatic Mali... Recurrent Malig... Refractory Neop... | Laboratory Biom... Metformin Pharmacological... Sapanisertib | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer | NCT02725268 | Endometrial Neo... | Paclitaxel Sapanisertib MLN1117 | 18 Years - | Takeda | |
| Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L) | NCT06385496 | Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult... | Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Sapanisertib | 18 Years - | National Cancer Institute (NCI) | |
| Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations | NCT03047213 | Locally Advance... Metastatic Tran... Metastatic Urot... Recurrent Bladd... Stage III Bladd... Stage IV Bladde... | Sapanisertib | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer | NCT05275673 | Non-Small Cell ... Squamous Non-sm... Squamous Non-Sm... NFE2L2 Gene Mut... | sapanisertib | 18 Years - | Calithera Biosciences, Inc | |
| Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer | NCT04250545 | Leptomeningeal ... Metastatic Lung... Metastatic Mali... Recurrent Lung ... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Sapanisertib Telaglenastat H... | 18 Years - | National Cancer Institute (NCI) | |
| Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers | NCT03017833 | Advanced Malign... Metastatic Mali... Recurrent Malig... Refractory Neop... | Laboratory Biom... Metformin Pharmacological... Sapanisertib | 18 Years - | M.D. Anderson Cancer Center | |
| Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer | NCT02503722 | Metastatic Lung... Recurrent Lung ... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... Stage IV Lung N... | Laboratory Biom... Osimertinib Pharmacological... Sapanisertib | 18 Years - | National Cancer Institute (NCI) | |
| Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma | NCT02133183 | Glioblastoma Gliosarcoma | Laboratory Biom... Pharmacological... Sapanisertib Therapeutic Con... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
